CD56(+bright) and CD56(+dim) natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis

Blood

Volumn 88, Issue 6, 1996, Pages 2279-2287

  Pierson, Bryce A ^a   Miller, Jeffrey S ^a,b  

^a University of Minnesota   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN;

ADULT; ARTICLE; CELL PROLIFERATION; CELL SUBPOPULATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY TEST; HUMAN; LEUKOCYTE COUNT; NATURAL KILLER CELL; PRIORITY JOURNAL;

EID: 0029823977     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.6.2279.bloodjournal8862279     Document Type: Article

References (39)

1. Dube ID, Gupta CM, Kalousek DK, Eaves CJ, Eaves AC: Cytogenetic studies of early myeloid progenitor compartments in Ph1 positive chronic myelogenous leukemia. Br J Haematol 56:633, 1984
2. Bernstein R: Cytogenetics of chronic myelogenous leukemia. Semin Hematol 25:20, 1988
3. DeKlein A, Van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D, Spurr NK, Heisterkamp N, Groffen J, Stephenson JR: A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. Nature 300:765, 1982
4. Mule JJ, Shu S, Schwarz SL, Rosenberg SA: Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225:1487, 1984
5. Miller JS, Klingsporn S, Lund J, Perry EH, Verfaillie C, McGlave P: Large-scale ex vivo expansion and activation of human natural killer cells for autologous therapy. Bone Marrow Transplant 14:555, 1994
6. Grimm EA, Mazumder A, Zhang HZ, Rosenberg S: Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823, 1982
7. Verfaillie C, Miller W, Kay N, McGlave PB: Adherent lymphokine-activated killer cells in chronic myelogenous leukemia: A benign cell population with potent cytotoxic activity. Blood 74:793, 1989
8. Gorelic E, Herberman RB: Role of natural killer (NK) cells in the control of tumor growth and metastatic spread, in Herberman RB (ed): Cancer Immunology: Innovative Approaches to Therapy. New York, NY, Martinus Nijhoff, 1986, p 151
9. Cervantes F, Pierson BA, McGlave PB, Verfaillie CM, Miller JS: Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture. Blood 87:2476, 1996
10. Lotzova E, Savary CA, Herberman RB: Induction of NK cell activity against fresh human leukemia in culture with interleukin-2. J Immunol 138:2718, 1987
11. Fujimyia Y, Bakke A, Cheng Chang W, Linker Israeli M, Udis B, Horwitz D, Pattengale PK: Natural killer cell immunodeficiency in patients with chronic myeloid leukemia I. Analysis of the deficit using the antibodies NKH1 (leu-7) and B73.1. J Cancer 37:639, 1986
12. Pawelec G, Schneider E, Ehninger G, Rehbein A, Schmidt H: Partial correction of defective generation of lymphokine-activated killer cells in patients with chronic myelogenous leukaemia after in vivo treatment with interferon-α (Wellferon). Cancer Immunol Immunother 29:63, 1989
13. Verfaillie C, Kay N, Miller W, McGlave PB: Diminished A-LAK cytotoxicity and proliferation accompanies disease progression in chronic myelogenous leukemia. Blood 76:401, 1990
14. Miller JS, Oelkers S, Verfaillie C, McGlave PB: Role of monocytes in the expansion of human activated natural killer cells. Blood 80:2221, 1992
15. Pierson BA, Miller JS, Verfaillie C, McGlave PB, Hu WS: Population dynamics of human activated natural killer cells in culture. Bioengineering Biotechnol 43:685, 1994
16. Nagler A, Lanier LL, Cwirla S, Phillips JH: Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol 143:3183, 1989
17. Ellis TM, Fisher RI: Functional heterogeneity of Leu 19"bright"+ and Leu 19"dim" + lymphokine-activated killer cells. J Immunol 142:2949, 1989
18. Nagler A, Lanier LL, Phillips JH: Constitutive expression of high affinity inlerleukin 2 receptors on human CD16- natural killer cells in vivo. J Exp Med 171:1527, 1990
19. Robertson MJ, Manley TJ, Donahue C, Levine H, Ritz J: Costimulatory signals are required for optimal proliferation of human natural killer cells. J Immunol 150:1705, 1993
20. Pierson BA, Gupta K, Hu WS, Miller JS: Human natural killer cell expansion is regulated by thrombospondin-mediated activation of TGF-β1 and independent accessory cell-derived contact and soluble factors. Blood 87:180, 1996
21. Pierson BA: Ex vivo expansion of human natural killer cells (NK) for adoptive immunotherapy. PhD Thesis, University of Minnesota, 1995
22. Pierson BA, McGlave PB, Hu WS, Miller JS: Natural killer cell proliferation is dependent on human serum and is markedly increased utilizing an enriched supplemented basal medium. J Hematother 4:149, 1995
23. Porter EH, Berry RJ: The efficient design of transplantable tumor assays. J Cancer 17:583, 1963
24. Taswell C: Limiting dilution assays for the determination of immunocompetent cell frequencies: I. Data analysis. J Immunol 126:1614, 1981
25. Matos ME, Schnier GS, Beecher MS, Ashman LK, Williams DE, Caligiuri MA: Expression of a functional c-kit receptor on a subset of natural killer cells. J Exp Med 178:1079, 1993
26. + NK progenitor. Blood 83:2594, 1994
27. - primitive progenitors in long-term bone marrow culture. Blood 80:2182, 1992
28. - bone marrow progenitors. J Immunol 150:5263, 1993
29. Silva MR, Hoffman R, Srour EF, Ascensao JL: Generation of human natural killer cells from immature progenitors does not require marrow stromal cells. Blood 84:841, 1994
30. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F, Castro-Malaspina H, Childs BH, Gillio AP, Kernan NA, Small TN, Young JW, O'Reilly RJ: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86:1261, 1995
31. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, van Rhee F, Mittermueller J, de Witte T, Holler E, Ansari H: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041, 1995
32. Hauch M, Gazzola MV, Small T, Bordignon C, Barnett L, Cunningham I, Castro-Malaspinia H, O'Reilly RJ, Keever CA: Antileukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood 75:2250, 1990
33. Chang W, Hsiao M, Pattengale P: Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia: IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer target binding and production of natural killer cytotoxic factor. Nat Immun Cell Growth Regul 10:57, 1991
34. Silla ML, Whiteside TL, Ball ED: The role of natural killer cells in the treatment of chronic myeloid leukemia. J Hematother 4:269, 1993
35. Miller JS, McGlave PB: Therapy for chronic myelogenous leukemia with marrow transplantation. Curr Opin Oncol 5:262, 1993
36. Bhatia R, Verfaillie CM: Autografting for chronic myelogenous leukemia. Curr Opin Hematol 2:436, 1995
37. van den Brink MRM, Voogt PJ, Marjit WAF, van Luxemburg-Heys SAP, van Rood JJ, Brand A: Lymphokine-activated killer cells selectively kill tumor cells in bone marrow without compromising bone marrow stem cell function in vitro. Blood 74:354, 1989
38. Charak BS, Brynes RK, Groshen S, Chen SC, Mazumder A: Bone marrow transplantation with interleukin-2-activated bone marrow followed by interleukin-2 therapy for acute myloid leukemia in mice. Blood 76:2187, 1990
39. Verma UN, Bagg A, Brown E, Mazumder A: Interleukin-2 activation of human bone marrow in long-term cultures: An effective strategy for purging and generation of anti-tumor cytotoxic effectors. Bone Marrow Transplant 13:115, 1994